Starting With Chemotherapy to Put Off Radiation in Widespread Glioblastoma
Original title: Multifocal Glioblastoma Managed With Primary Temozolomide as a Strategy to Delay Radiation Therapy: Clinical and Radiological Outcomes.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a small look back at past patients, not a real trial.
The short version
Doctors tried chemotherapy first to delay radiation, but most tumors still came back.
What was studied. Doctors looked back at 18 adults with newly found glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary in more than one spot. Each one started with the chemotherapy drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary instead of radiation.
What they found. Patients took about six rounds of the drug. At 6 months, 61% had no sign of the tumor growing. The tumor came back in 94.4% of them, which was 17 people. Half of the patients were still alive at 12.2 months.
What this means, and what it doesn't
What it could mean: This plan may buy a little time before radiation starts. Radiation over a large part of the brain can be hard on a person. But this approach did not hold the tumor back for long.
What it doesn't mean: This does not mean chemotherapy first is better than usual care. It is not a cure. This was a small look back at 18 patients, not a trial that compared two groups. The tumor came back in almost everyone. The doctors call it an early, exploratory idea. It is still far from everyday care.
Source: PubMed, October 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.